Pathology of Urinary Bladder Paraganglioma
Updated: Jun 06, 2019
Author: Zhong Jiang, MD; Chief Editor: Liang Cheng, MD
Definition
Urinary bladder paraganglioma is a rare neoplasm that originates from the paraganglion cells of the urinary bladder and is the same as paraganglioma at other anatomic sites. The tumor arises from the ganglion cell in the bladder wall. Paragangliomas account for less than 0.06% of all bladder tumors[1, 2, 3] and occur in all age groups.[4, 5, 6]
Rarely, paraganglioma of the urinary bladder is associated with neurofibromatosis and urothelial carcinoma. Genetic testing is recommended for patients because up to 25% of apparently sporadic cases are associated with a hereditary syndrome.[7, 8]
Clinical Features and Imaging
As with other bladder tumors, hematuria is the most common symptom of bladder paraganglioma.[3] A more tumor-specific feature is persistent hypertension. Because the paraganglioma secretes catecholamines, patients may have symptoms of headache, sweating, tremulousness, anxiety, and micturition syncope (the temporary loss of consciousness upon urinating).[1, 2, 9] Laboratory tests for catecholamine and its metabolites in serum and urine, as well as immunohistochemical studies (particularly in those with succinate dehydrogenase [SDH] B germline and somatic mutations[10] ), can often help in establishing the diagnosis.[11]
Localized tumors are generally treated by transurethral resection, wedge resection, or partial cystectomy. Malignant bladder paragangliomas are usually treated with radical cystectomy and tumor removal.
Differential diagnosis
Paraganglioma of the urinary bladder may mimic high-grade urothelial carcinoma with a nest pattern. The differential diagnosis may also include melanoma and carcinoid tumor. Immunohistochemical stains are useful in helping to establish these diagnoses. Urothelial carcinoma and carcinoid tumor are positive for cytokeratin, whereas melanoma cells show positivity of S100, HMB45, and Melan A stains.
Gross Findings
Paraganglia are distributed throughout the bladder wall; thus, paraganglioma can be found in any part of the urinary bladder. These tumors are mostly well circumscribed, and they form single small nodules, ranging from a few millimeters to a couple of centimeters. (Intramural and subserosal tumors are generally large and functional.[12] ) Multiple tumor nodules or tumoral aggregates are also seen. Placing the tumor in a Zenker fixative turns the tumor color to black; a positive chromaffin reaction helps in the gross diagnosis of the tumor.
Microscopic Findings
There is no standard staging system for paraganglioma.[7, 13] Paragangliomas of the urinary bladder may be benign or malignant; however, large tumor size, an increased number of mitoses, and the presence of lymphovascular tumor invasion and succinate dehydrogenase (SDH) B mutations make malignant paraganglioma more likely.[14] DNA aneuploidy and extensive tumor necrosis are also associated with malignancy.[7, 13]
Histologic features of the tumor are the same as in paraganglioma of other organs, including adrenal pheochromocytoma. The tumor cells grow in a zellballen pattern and are embedded in a fibrous network that is rich with blood vessels (see the following images).
Paraganglioma of the urinary bladder. Microscopic appearance of bladder paraganglioma, low magnification. Tumor cells grow in a zellballen pattern and are embedded in a fibrous network that is rich with blood vessels.
Paraganglioma of the urinary bladder. Microscopic appearance of bladder paraganglioma, high magnification. Tumor cells grow in a zellballen pattern and are embedded in a fibrous network that is rich with blood vessels.
Round tumor cells have amphophilic or acidophilic cytoplasm, containing dense granules as identified by ultrastructure study, and round or ovoid nuclei. Bizarre nuclei can be seen but have no significance. Mitosis is rare, but vascular invasion and invasive growth pattern can be present. Desmoplastic reaction is absent.
Immunohistochemistry
Paraganglioma of the urinary bladder, as in other organs, usually does not react to epithelium-specific antibodies. The tumor cells are positive for neuroendocrine markers, such as chromogranin and synaptophysin, but are negative for epithelial markers, including cytokeratin and epithelial membrane antigen (EMA). Sustentacular cells of the tumor are positive for S100 protein, and they form a characteristic pattern of staining around the tumor nest.[4, 15, 16, 17]
Prognosis and Predictive Factors
The prognosis of paraganglioma of the urinary bladder is typically favorable for localized tumors.[13] However, patients require life-long follow-up to detect late recurrences.[1] Risk factors for recurrence and metastasis of functional tumors include advanced classification (≥T3), multifocal tumors, and CgA (glycoprotein hormones, alpha polypeptide) expression.[9]
About 15%-20% of paraganglioma of the urinary bladder cases can develop metastasis,[1] and metastasis is the only reliable indicator of malignancy for this tumor.[15] Vascular invasion, a deeply invasive growth pattern, and recurrence are associated with a poor prognosis. Additional risk factors for malignancy include young age, larger tumor size, higher Ki67 proliferation rate, and catecholamine type.[18]
Author
Zhong Jiang, MD Professor, Department of Pathology, University of Massachusetts, Memorial Medical Center
Zhong Jiang, MD is a member of the following medical societies: College of American Pathologists, United States and Canadian Academy of Pathology, International Society of Urological Pathology
Disclosure: Nothing to disclose.
Chief Editor
Liang Cheng, MD Virgil H Moon Professor of Pathology and Laboratory Medicine, Professor of Urology, Director of Molecular Diagnostics and Molecular Pathology Laboratory, Indiana University School of Medicine; Chief, Genitourinary Pathology Service, Indiana University Health
Liang Cheng, MD is a member of the following medical societies: American Association for Cancer Research, American Urological Association, Arthur Purdy Stout Society, College of American Pathologists, International Society of Urological Pathology, United States and Canadian Academy of Pathology
Disclosure: Nothing to disclose.
Additional Contributors
Di Lu, MD Clinical Associate Professor, Department of Pathology, University of Massachusetts Medical School
Disclosure: Nothing to disclose.
Al-Zahrani AA. Recurrent urinary bladder paraganglioma. Adv Urol. 2010. 912125. [QxMD MEDLINE Link]. [Full Text].
Pahwa HS, Kumar A, Srivastava R, Rai A. Unsuspected pheochromocytoma of the urinary bladder: reminder of an important clinical lesson. BMJ Case Rep. 2012 Aug 8. 2012:[QxMD MEDLINE Link]. [Full Text].
Iwamoto G, Kawahara T, Tanabe M, et al. Paraganglioma in the bladder: a case report. J Med Case Rep. 2017 Oct 31. 11 (1):306. [QxMD MEDLINE Link].
Cheng L, Leibovich BC, Cheville JC, et al. Paraganglioma of the urinary bladder: can biologic potential be predicted?. Cancer. 2000 Feb 15. 88(4):844-52. [QxMD MEDLINE Link].
Heinrich E, Gattenloehner S, Mueller-Hermelink HK, Michel MS, Schoen G. Paraganglioma of urinary bladder. Urol J. 2008 Winter. 5(1):57-9. [QxMD MEDLINE Link].
Linnoila RI, Keiser HR, Steinberg SM, Lack EE. Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features. Hum Pathol. 1990 Nov. 21(11):1168-80. [QxMD MEDLINE Link].
National Cancer Institute. Pheochromocytoma and paraganglioma treatment (PDQ)–Health professional version. Available at https://www.cancer.gov/types/pheochromocytoma/hp/pheochromocytoma-treatment-pdq. February 8, 2018; Accessed: June 6, 2019.
Bohn OL, Pardo-Castillo E, Fuertes-Camilo M, Rios-Luna NP, Martinez A, Sanchez-Sosa S. Urinary bladder paraganglioma in childhood: a case report and review of the literature. Pediatr Dev Pathol. 2011 Jul-Aug. 14 (4):327-32. [QxMD MEDLINE Link].
Deng JH, Li HZ, Zhang YS, Liu GH. Functional paragangliomas of the urinary bladder: a report of 9 cases. Chin J Cancer. 2010 Aug. 29 (8):729-34. [QxMD MEDLINE Link].
Giubellino A, Lara K, Martucci V, et al. Urinary bladder paragangliomas: how immunohistochemistry can assist to identify patients with SDHB germline and somatic mutations. Am J Surg Pathol. 2015 Nov. 39 (11):1488-92. [QxMD MEDLINE Link]. [Full Text].
Menon S, Goyal P, Suryawanshi P, Tongaonkar H, Joshi A, Bakshi G, et al. Paraganglioma of the urinary bladder: a clinicopathologic spectrum of a series of 14 cases emphasizing diagnostic dilemmas. Indian J Pathol Microbiol. 2014 Jan-Mar. 57 (1):19-23. [QxMD MEDLINE Link].
Lu H, Male M, Jiang K, Ye Z, Song D, Xia D. Clinical significance of functional and anatomical classifications in paraganglioma of the urinary bladder. Urol Oncol. 2019 Jun. 37 (6):354.e9-354.e17. [QxMD MEDLINE Link].
Beilan JA, Lawton A, Hajdenberg J, Rosser CJ. Pheochromocytoma of the urinary bladder: a systematic review of the contemporary literature. BMC Urol. 2013 Apr 29. 13:22. [QxMD MEDLINE Link]. [Full Text].
Park S, Kang SY, Kwon GY, et al. Clinicopathologic characteristics and mutational status of succinate dehydrogenase genes in paraganglioma of the urinary bladder: a multi-institutional Korean Study. Arch Pathol Lab Med. 2017 May. 141 (5):671-7. [QxMD MEDLINE Link].
Safwat AS, Bissada NK. Pheochromocytoma of the urinary bladder. Can J Urol. 2007 Dec. 14(6):3757-60. [QxMD MEDLINE Link].
Grignon DJ, Ro JY, Mackay B, et al. Paraganglioma of the urinary bladder: immunohistochemical, ultrastructural, and DNA flow cytometric studies. Hum Pathol. 1991 Nov. 22(11):1162-9. [QxMD MEDLINE Link].
Kairi-Vassilatou E, Argeitis J, Nika H, Grapsa D, Smyrniotis V, Kondi-Pafiti A. Malignant paraganglioma of the urinary bladder in a 44-year-old female: clinicopathological and immunohistochemical study of a rare entity and literature review. Eur J Gynaecol Oncol. 2007. 28(2):149-51. [QxMD MEDLINE Link].
Gupta S, Zhang J, Rivera M, Erickson LA. Urinary bladder paragangliomas: analysis of succinate dehydrogenase and outcome. Endocr Pathol. 2016 Sep. 27 (3):243-52. [QxMD MEDLINE Link].
Kouba E, Cheng L. Neuroendocrine tumors of the urinary bladder according to the 2016 World Health Organization classification: molecular and clinical characteristics. Endocr Pathol. 2016 Sep. 27 (3):188-99. [QxMD MEDLINE Link].